Clinical Trials Logo

Mucopolysaccharidosis III clinical trials

View clinical trials related to Mucopolysaccharidosis III.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06333041 Not yet recruiting - Sanfilippo Syndrome Clinical Trials

Study of Cannabidiol in Sanfilippo Syndrome

Start date: May 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial is to test cannabidiol in Sanfilippo syndrome. The main questions it aims to answer are: 1) determine the safety of cannabidiol in Sanfilippo syndrome, and 2) explore the efficacy of cannabidiol in treating the neurobehavioral symptoms and functional outcomes of Sanfilippo syndrome. Each participant's caregiver will be asked to complete surveys related to the participant's behavior, mood, sleep, stooling, pain, and caregiver stress intermittently throughout the study. All participants will be enrolled into one of two cohorts based on enrollment order: 1. Sentinel Safety Cohort (first 5 participants) - all participants treated with Epidiolex (cannabidiol) 2. Controlled Cohort (next 30 participants) - participants randomized 1:1 (equal chance) to start treatment with Epidiolex (cannabidiol) or placebo for 16 weeks, followed by an 8-week washout period (no treatment). Participants then switch to the opposite treatment group for 16 weeks followed by all participants treated for 52 weeks with Epidiolex (cannabidiol).

NCT ID: NCT05825131 Not yet recruiting - Clinical trials for Sanfilippo Syndrome Type C

Natural History Study of Participants With Sanfilippo Syndrome Type IIIC

MPSIIIC
Start date: June 10, 2024
Phase:
Study type: Observational [Patient Registry]

This study is planned to document, through retrospective and prospective data collection, syndrome progression in children and young adults with MPS IIIC.

NCT ID: NCT04918641 Not yet recruiting - Clinical trials for Sanfilippo Syndrome A

Natural History Observational Study of MPS IIIa in SMC

Start date: June 30, 2021
Phase:
Study type: Observational [Patient Registry]

To characterize the clinical course of mucopolysaccharidosis type IIIA (MPS IIIA), and identify potential endpoints for future treatment trials.